Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Statement

14 May 2021 07:00

RNS Number : 5928Y
Sabre Insurance Group PLC
14 May 2021
 

 

14 May 2021

SABRE INSURANCE GROUP PLC

 

Trading Update

 

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides an update on trading for the period to 30 April 2021 ahead of its AGM later this morning.

- Continued focus on prioritising underwriting profitability over volume, with price increases materially ahead of the market

- Overall, volumes for the first quarter of the year are in line with our expectations

- Gross written premium for the four months to 30 April 2021 was £46.0m (four months to 30 April 2020: £54.6m)

- Continued strong organic capital generation with a solvency coverage ratio of 171% post-dividend as at 31 March 2021 (31 December 2020: 155%)

- Too early to identify meaningful market quote volume increases as lockdown eases, however:

- throughout April, volumes were ahead of the comparative period in 2020

- clear visibility on premium outturn for the full year remains limited at this point due to numerous intertwined regulatory, market and COVID impacts

- combined ratio for the financial year is expected to be within the target range of 70% to 80%

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"Volumes through Q1 were in line with our expectations, during which we continued to execute our strategy of focusing on profitability over volume. Alongside that, we continue to investigate and implement new rating factors and potential new, complementary product offerings which will help drive disciplined and profitable volume growth in future periods.

While we are still in the very early stages of an easing in the lockdown restrictions, through April we have started to see some increase in our premium levels, and the policy count has enjoyed modest growth. Premiums in April were 14.6% higher than the same period last year, with the weekly run-rate increasing relative to 2020 towards the end of the month and into the first week of May. This is despite us being consistent with regard to our pricing discipline and against a backdrop of low quote volumes across the market.

Looking forward, we remain confident that volumes will increase as the number of drivers and car sales increase. We also expect that - in due course - the FCA pricing review, changes to small bodily injury claims ("whiplash reforms") and ongoing claims inflation will drive some competitors to increase prices materially.

Our claims performance and organic capital generation was strong, and we remain confident of providing an attractive dividend for the year, possibly through the utilisation of our robust capital range. While short term visibility remains limited, we remain confident that our agility and tried-and-tested strategy will deliver a strong result for the year.

Finally, we are delighted to have appointed Matthew Wright as our new Chief Actuary after a near 12-month transition period and seven years with Sabre. We are confident Matt will be able to further enhance our market leading pricing capabilities."

 

Investor enquiries

01306 747272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Tulchan Communications

sabre@tulchangroup.com

James Macey White

David Allchurch

Giles Kernick

The Sabre Insurance Group plc LEI number is 2138006RXRQ8P8VKGV98

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDUSXBDGBX
Date   Source Headline
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20257:00 amRNSTransaction in Own Shares
17th Jun 20254:35 pmRNSDirector/PDMR Shareholding
11th Jun 20251:38 pmRNSDirector/PDMR Shareholding
5th Jun 202511:16 amRNSDirector/PDMR Shareholding
22nd May 202511:38 amRNSResult of AGM
22nd May 20257:00 amRNSTrading Update
13th May 20253:18 pmRNSDirector/PDMR Shareholding
17th Apr 20259:40 amRNSDirector/PDMR Shareholding
11th Apr 20251:26 pmRNSDirector/PDMR Shareholding
10th Apr 20251:09 pmRNSDirector/PDMR Shareholding
8th Apr 20254:31 pmRNSDirector/PDMR Shareholding
8th Apr 20253:54 pmRNSDirector/PDMR Shareholding
8th Apr 20251:53 pmRNSDirector/PDMR Shareholding
4th Apr 20253:20 pmRNSNotice of AGM
27th Mar 20258:37 amRNSDirector/PDMR Shareholding
20th Mar 202511:39 amRNSDirector/PDMR Shareholding
18th Mar 20257:00 amRNSFinal Results
11th Mar 20251:21 pmRNSDirector/PDMR Shareholding
24th Feb 202511:23 amRNSNotice of Results
11th Feb 20253:12 pmRNSDirector/PDMR Shareholding
13th Jan 20252:14 pmRNSDirector/PDMR Shareholding
11th Dec 202411:57 amRNSDirector/PDMR Shareholding
5th Dec 20247:00 amRNSCapital Markets Event
21st Nov 202410:28 amRNSAppointment of Joint Corporate Broker
12th Nov 20241:15 pmRNSDirector/PDMR Shareholding
23rd Oct 20244:13 pmRNSHolding(s) in Company
22nd Oct 20242:43 pmRNSDirector/PDMR Shareholding
22nd Oct 20242:40 pmRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update
18th Oct 20243:25 pmRNSHolding(s) in Company
11th Oct 202412:40 pmRNSDirector/PDMR Shareholding
26th Sep 20241:25 pmRNSDirector/PDMR Shareholding
11th Sep 202412:21 pmRNSDirector/PDMR Shareholding
11th Sep 20249:51 amRNSHolding(s) in Company
6th Sep 20242:29 pmRNSHolding(s) in Company
30th Aug 202411:50 amRNSDirector/PDMR Shareholding
22nd Aug 20244:22 pmRNSHolding(s) in Company
14th Aug 20243:33 pmRNSHolding(s) in Company
13th Aug 202412:48 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSHalf-year Report 2024
22nd Jul 20247:00 amRNSNotice of Results
11th Jul 202412:25 pmRNSDirector/PDMR Shareholding
3rd Jul 20243:40 pmRNSHolding(s) in Company
19th Jun 202412:28 pmRNSAppointment of Non-executive Director
14th Jun 20249:50 amRNSDirector/PDMR Shareholding
11th Jun 202411:54 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.